Publications by authors named "Febe Smits"

Claim this Profile
A
Adaptive designs in randomized clinical trials: reanalysis of the HOVON87/NMSG18 multiple myeloma trial.
Maarten R Seefat, Niek G van der Maas, Kazem Nasserinejad, Bronno van der Holt, Anders Waage, Febe Smits

EClinicalMedicine· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome.
Kazimierz Groen, Febe Smits, Kazem Nasserinejad, Mark-David Levin, Josien C Regelink

Hemasphere· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy.
Wassilis S C Bruins, Febe Smits, Carolien Duetz, Kaz Groen, Charlotte L B M Korst

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.
Febe Smits, Kaz Groen, Mark-David Levin, Claudia A M Stege, Roel van Kampen

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Two Sides of Bispecific Antibodies in Multiple Myeloma: Where Trial Promise Meets Real-World Practice.
Sonja Zweegman, Febe Smits, Niels W C J van de Donk

Blood Cancer Discov· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels.
Wassilis S C Bruins, Febe Smits, Carolien Duetz, Kazem Nasserinejad, Kazimierz Groen

Hemasphere· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy.
Charlotte L B M Korst, Sabrin Tahri, Carolien Duetz, Wassilis S C Bruins, A Vera de Jonge, Febe Smits

Blood· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma.
Febe Smits, Kaz Groen, Mark-David Levin, Claudia A M Stege, Roel van Kampen

Blood· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes.
Kazimierz Groen, Febe Smits, Kazem Nasserinejad, Mark-David Levin, Josien C Regelink

Hemasphere· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Febe Smits, Bart Torensma, Rolf Groenwold, Maurine Leversteijn-Van Hall, Nathalie van Burgel

Huisarts Wet· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of Carpal Tunnel Release and the Relation With Depression.
Mirjam Datema, Martijn R Tannemaat, Elske Hoitsma, E W van Zwet, Febe Smits

J Hand Surg Am· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis